• Exemestane: Applied Workflows for Steroidal Aromatase Inhibi

  2026-04-30

  Exemestane stands out as a potent, irreversible steroidal aromatase inhibitor, uniquely suited for precise estrogen biosynthesis inhibition in breast cancer research. This article details advanced assay setups, workflow optimizations, and troubleshooting strategies to harness Exemestane's molecular properties for reproducible, high-impact results.

• Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Ther

  2026-04-30

  This study pioneers a hyaluronated lipid nanoparticle (HA-LNP) system for the non-invasive, transdermal delivery of PTEN tumor suppressor gene mRNA, targeting melanoma models. By restoring PTEN expression and enhancing antitumor immunity, the platform addresses immune evasion and resistance to checkpoint inhibitors, offering a clinically relevant approach for localized mRNA-based cancer immunotherapy.

• GRK Subtype Bias in M1 Receptor Signaling: Mechanistic Insig

  2026-04-29

  This study delineates how distinct GRK subtypes differentially modulate M1 muscarinic acetylcholine receptor (mAChR) signaling bias, affecting downstream G protein and β-arrestin pathways. By applying quantitative BRET assays with multiple agonists and modulators—including BQCA—the research advances mechanistic understanding crucial for targeted cognitive and Alzheimer's disease research.

• Astrocytic GAT-3 Controls Synaptic Transmission in the Denta

  2026-04-29

  This study uncovers how astrocytic GAT-3 regulates synaptic transmission and memory formation in the dentate gyrus by modulating astrocytic Ca2+ signaling and glutamatergic activity. These findings elucidate a critical astrocyte-mediated mechanism underlying hippocampal function and highlight GAT-3 as a potential therapeutic target for cognitive disorders.

• RIG-I Drives Renal Fibrosis via c-Myc and Tubular Epithelial

  2026-04-28

  This study identifies RIG-I as a key driver of renal interstitial fibrosis, acting through c-Myc-mediated activation of fibroblasts and proinflammatory cytokine production in tubular epithelial cells. The findings advance mechanistic understanding of chronic kidney disease progression and offer experimentally supported targets for future antifibrotic strategies.

• Ziprasidone Targets GOT1 to Suppress Pancreatic Cancer Growt

  2026-04-28

  This study reveals that ziprasidone functions as a novel non-competitive inhibitor of glutamate-oxaloacetate transaminase 1 (GOT1), disrupting glutamine metabolism and suppressing pancreatic ductal adenocarcinoma (PDAC) cell proliferation. The findings suggest GOT1 inhibition as a promising metabolic vulnerability in PDAC, with implications for future metabolic-targeted therapies.

• EdU Imaging Kits (Cy3): Applied S-Phase DNA Synthesis Detect

  2026-04-27

  APExBIO’s EdU Imaging Kits (Cy3) deliver unrivaled sensitivity for measuring cell proliferation via click chemistry, streamlining workflows in genotoxicity testing and cancer biology. This guide translates recent prostate cancer research into actionable protocols, troubleshooting insights, and real-world assay optimization.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-04-27

  This study introduces a novel glabridin-gold(I) (6d) complex that synergistically targets thioredoxin reductase and MAPK pathways to modulate the tumor microenvironment and enhance antitumor immunity. The findings highlight the mechanistic basis for dual-targeting metal-based immunomodulators, with implications for improving cancer immunotherapy outcomes.

• Glabridin-Gold(I) Complex Targets TrxR and MAPK for Tumor Im

  2026-04-26

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets the TrxR and MAPK pathways to enhance antitumor immunity in liver cancer. By promoting dendritic cell maturation and reducing immunosuppressive cell populations, 6d represents a promising strategy for overcoming tumor microenvironment barriers in immunotherapy.

• Adefovir (SKU C6629): Data-Driven Lab Solutions for HBV Rese

  2026-04-25

  This article provides a scenario-driven, evidence-based guide to using Adefovir (SKU C6629) for hepatitis B virus research and transporter assays. Drawing on recent pharmacokinetic studies and practical workflow tips, it demonstrates how Adefovir’s specificity and validated protocol parameters enable reproducible, high-impact results. Researchers will find actionable recommendations for experimental design, data interpretation, and vendor selection.

• Strategic Cathepsin B Inhibition: Transforming Translational

  2026-04-24

  This thought-leadership article examines the mechanistic and translational impact of Cathepsin B inhibition—highlighting CA-074 (APExBIO)—in the context of cancer metastasis, neurotoxicity, and immune modulation. Integrating recent mechanistic breakthroughs, including MLKL-driven lysosomal membrane permeabilization in necroptosis, we provide actionable guidance and strategic considerations for translational researchers. The article benchmarks CA-074’s selectivity, discusses experimental protocols, and outlines the next frontiers in cathepsin B–targeted research.

• Alcian Blue & Nuclear Fast Red Staining Kit: Precision in Mu

  2026-04-24

  Unlock streamlined, dual-color histological staining for acid mucopolysaccharides and nuclei in tissue sections. The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, empowers high-contrast chondrogenic differentiation assays and enhances mucin detection workflows, setting new standards for reproducibility and tissue clarity.

• Amphotericin B: Mechanistic Insight and Strategy for Transla

  2026-04-23

  This thought-leadership article decodes the multifaceted mechanism of Amphotericin B, a polyene antifungal antibiotic, and offers strategic guidance for translational researchers tackling fungal infection resistance and biofilm-associated drug failure. Drawing on recent peer-reviewed findings, with a spotlight on Candida albicans biofilms and translational prion disease models, we provide actionable recommendations for leveraging APExBIO’s rigorously validated Amphotericin B to drive reproducibility and innovation in advanced experimental workflows. The discussion escalates beyond standard product pages by integrating mechanistic, immunological, and workflow-focused perspectives, and by critically evaluating future directions and limitations.

• Etoposide (VP-16): Applied Workflows for DNA Damage Assays

  2026-04-23

  Leverage Etoposide (VP-16) to reliably induce DNA double-strand breaks and apoptosis in cancer cell models. This guide distills practical workflows, troubleshooting, and nuanced protocol enhancements—empowering researchers to maximize experimental success in DNA damage assay and cancer chemotherapy research.

• Neomycin Sulfate: Unraveling Mechanistic Insights and Immune

  2026-04-22

  Explore the unique mechanistic actions of Neomycin sulfate, a leading aminoglycoside antibiotic, with deep analysis on its RNA/DNA interactions and immune modulation. Discover how new research and advanced protocols expand its value for molecular biology.

15590 records 1/1040 page Next 12345 下5页 Last page